-

Agilent Announces BioTek 406 FX Washer Dispenser for Technology-Driven Workflow Efficiency

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of the Agilent BioTek 406 FX washer dispenser, a compact instrument that combines multifunctional reagent dispensing and plate-washing capabilities. The BioTek 406 FX offers expanded liquid handling features designed for integration into automated systems and standalone benchtop use.

Key features of the new BioTek 406 FX improve upon the benefits of the first-generation EL406 and include:

  • Secondary peristaltic and dual syringe pumps.
  • A touchscreen interface.
  • Enhanced flexibility for automated workflows across a broad range of applications, such as cell-based and magnetic bead-based assays. 

The additional reagent dispense pumps enable up to six different reagents to be dispensed using the pump technology best suited to each step of the workflow. Combining multiple assay workflow step capabilities in a single instrument is expected to be particularly beneficial for laboratories confronting space and budgetary constraints. The 406 FX plate carrier can be accessed from the right or left side, making it ideally suited for integration into robotic systems.

Caleb Foster, associate vice president of marketing for Agilent's Cell Analysis Division, discussed the impact of the release. "The launch of the 406 FX is an exciting step in the evolution of the Agilent BioTek liquid handling product line – one that incorporates years of customer feedback received from the EL406," he said. "This flexible platform replaces several instruments in one, with market-leading multifunctional capabilities.”

“It's a true workhorse instrument that can be used for cell-based assays, ELISA, and many other microplate-based workflows, and it brings the flexibility and reliability customers have come to expect from our products,” Foster added.

BioTek microplate washer dispensers are used widely throughout the life sciences industry. They are an integral part of a suite of automation-friendly Agilent solutions that aim to improve throughput and ease of use in complex end-to-end cell analysis workflows.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Naomi Goumillout
Agilent Technologies Inc.
+1.978.314.1862
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Naomi Goumillout
Agilent Technologies Inc.
+1.978.314.1862
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a founda...

Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company’s expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing so...

Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions

SANTA CLARA, Calif. & SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million. Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in sit...
Back to Newsroom